174 related articles for article (PubMed ID: 23725202)
1. The 'peptidome' of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity.
Graner MW; Romanoski A; Katsanis E
Int J Hyperthermia; 2013 Aug; 29(5):380-9. PubMed ID: 23725202
[TBL] [Abstract][Full Text] [Related]
2. Proteomic analyses of different human tumour-derived chaperone-rich cell lysate (CRCL) anti-cancer vaccines reveal antigen content and strong similarities amongst the vaccines along with a basis for CRCL's unique structure: CRCL vaccine proteome leads to unique structure.
Mayer-Sonnenfeld T; Har-Noy M; Lillehei KO; Graner MW
Int J Hyperthermia; 2013 Sep; 29(6):520-7. PubMed ID: 23734882
[TBL] [Abstract][Full Text] [Related]
3. Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia.
Kislin KL; Marron MT; Li G; Graner MW; Katsanis E
FASEB J; 2007 Jul; 21(9):2173-84. PubMed ID: 17327358
[TBL] [Abstract][Full Text] [Related]
4. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens.
Bleifuss E; Bendz H; Sirch B; Thompson S; Brandl A; Milani V; Graner MW; Drexler I; Kuppner M; Katsanis E; Noessner E; Issels RD
Int J Hyperthermia; 2008 Dec; 24(8):623-37. PubMed ID: 18608582
[TBL] [Abstract][Full Text] [Related]
5. Natural killer cells play a key role in the antitumor immunity generated by chaperone-rich cell lysate vaccination.
Zeng Y; Chen X; Larmonier N; Larmonier C; Li G; Sepassi M; Marron M; Andreansky S; Katsanis E
Int J Cancer; 2006 Dec; 119(11):2624-31. PubMed ID: 16989012
[TBL] [Abstract][Full Text] [Related]
6. Intracellular and extracellular Hsp70 chaperone as a target for cancer therapy.
Guzhova IV; Shevtsov MA; Abkin SV; Pankratova KM; Margulis BA
Int J Hyperthermia; 2013 Aug; 29(5):399-408. PubMed ID: 23845032
[TBL] [Abstract][Full Text] [Related]
7. Tumour secreted grp170 chaperones full-length protein substrates and induces an adaptive anti-tumour immune response in vivo.
Arnouk H; Zynda ER; Wang XY; Hylander BL; Manjili MH; Repasky EA; Subjeck JR; Latif Kazim A
Int J Hyperthermia; 2010; 26(4):366-75. PubMed ID: 20210603
[TBL] [Abstract][Full Text] [Related]
8. Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96.
Ishii T; Udono H; Yamano T; Ohta H; Uenaka A; Ono T; Hizuta A; Tanaka N; Srivastava PK; Nakayama E
J Immunol; 1999 Feb; 162(3):1303-9. PubMed ID: 9973383
[TBL] [Abstract][Full Text] [Related]
9. Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma.
Graner M; Raymond A; Romney D; He L; Whitesell L; Katsanis E
Clin Cancer Res; 2000 Mar; 6(3):909-15. PubMed ID: 10741715
[TBL] [Abstract][Full Text] [Related]
10. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity.
Zeng Y; Feng H; Graner MW; Katsanis E
Blood; 2003 Jun; 101(11):4485-91. PubMed ID: 12576309
[TBL] [Abstract][Full Text] [Related]
11. Chaperone-rich cell lysates, immune activation and tumor vaccination.
Zeng Y; Graner MW; Katsanis E
Cancer Immunol Immunother; 2006 Mar; 55(3):329-38. PubMed ID: 15887013
[TBL] [Abstract][Full Text] [Related]
12. Dual role of heat shock proteins as regulators of apoptosis and innate immunity.
Joly AL; Wettstein G; Mignot G; Ghiringhelli F; Garrido C
J Innate Immun; 2010; 2(3):238-47. PubMed ID: 20375559
[TBL] [Abstract][Full Text] [Related]
13. Message in a bottle: role of the 70-kDa heat shock protein family in anti-tumor immunity.
Calderwood SK; Theriault JR; Gong J
Eur J Immunol; 2005 Sep; 35(9):2518-27. PubMed ID: 16144035
[TBL] [Abstract][Full Text] [Related]
14. HSP110 induces "danger signals" upon interaction with antigen presenting cells and mouse mammary carcinoma.
Manjili MH; Park J; Facciponte JG; Subjeck JR
Immunobiology; 2005; 210(5):295-303. PubMed ID: 16164037
[TBL] [Abstract][Full Text] [Related]
15. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin.
Basu S; Binder RJ; Ramalingam T; Srivastava PK
Immunity; 2001 Mar; 14(3):303-13. PubMed ID: 11290339
[TBL] [Abstract][Full Text] [Related]
16. Potent tumor-specific immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine.
Ren W; Strube R; Zhang X; Chen SY; Huang XF
Cancer Res; 2004 Sep; 64(18):6645-51. PubMed ID: 15374979
[TBL] [Abstract][Full Text] [Related]
17. Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine.
Casey DG; Lysaght J; James T; Bateman A; Melcher AA; Todryk SM
Immunology; 2003 Sep; 110(1):105-11. PubMed ID: 12941147
[TBL] [Abstract][Full Text] [Related]
18. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells.
Castelli C; Ciupitu AM; Rini F; Rivoltini L; Mazzocchi A; Kiessling R; Parmiani G
Cancer Res; 2001 Jan; 61(1):222-7. PubMed ID: 11196165
[TBL] [Abstract][Full Text] [Related]
19. [Preparation of chaperone-antigen peptide vaccine derived from human gastric cancer stem cells and its immune function].
Jiang YQ; Guo QM; Xu XP; Liang JC; He YY; An SH; Su F; Li CY; Huang CX
Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):109-114. PubMed ID: 28219205
[No Abstract] [Full Text] [Related]
20. Melanoma cell necrosis facilitates transfer of specific sets of antigens onto MHC class II molecules of dendritic cells.
Röhn TA; Schadendorf D; Sun Y; Nguyen XD; Roeder D; Langen H; Vogt AB; Kropshofer H
Eur J Immunol; 2005 Oct; 35(10):2826-39. PubMed ID: 16163671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
